China’s new commercial insurance model could broaden access to Alzheimer’s drugsnews2025-12-22T18:18:09+00:00December 22nd, 2025|Endpoints News|
Windward gets bispecific from Qyuns in its second China deal of the yearnews2025-12-22T15:46:03+00:00December 22nd, 2025|Endpoints News|
Ipsen gains access to ADC from Shanghai biotech Simcere Zaimingnews2025-12-22T14:12:36+00:00December 22nd, 2025|Endpoints News|
Joe Jimenez’s Aditum goes to Fosun for major biobuck-loaded collaborationnews2025-12-19T13:15:31+00:00December 19th, 2025|Endpoints News|
US commission urges action as China’s biotech sector advancesnews2025-12-19T05:01:37+00:00December 19th, 2025|Endpoints News|
Senate passes Biosecure Act aimed at Chinese suppliersnews2025-12-17T18:25:23+00:00December 17th, 2025|Endpoints News|
RTW’s Yarrow to go public in reverse merger with Vyne Therapeuticsnews2025-12-17T15:47:20+00:00December 17th, 2025|Endpoints News|
Harbour makes $90M upfront deal with Bristol Myers for new antibodiesnews2025-12-17T00:03:06+00:00December 17th, 2025|Endpoints News|
RTW startup signs autoimmune antibody pact with China’s GenScinews2025-12-16T12:28:24+00:00December 16th, 2025|Endpoints News|
InnoCare says Zenas-partnered drug succeeds in China study in form of lupusnews2025-12-15T16:15:00+00:00December 15th, 2025|Endpoints News|
